EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study

Zafer Bağcı, Rukiye Uyanık, Ümmügülsüm Can, Deniz Yılmaz, Sadinaz Akdu

Frontiers in Pediatrics · 18.08.2026 · 14

DOI: 10.3389/fped.2026.1935719 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Frontiers in Pediatrics, online erschienen am 18.08.2026. Verfasst von Zafer Bağcı und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Konya City Hospital, University of Health Sciences, Konya, Türkiye. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phoenixin is a novel neuropeptide encoded by the SMIM20 gene, implicated in energy homeostasis and reproduction, but its role in pediatric metabolic syndrome remains unknown.

Methods

This cross-sectional study enrolled 98 children and adolescents aged 7–18 years [45 with Metabolic syndrome (MetS) and 53 with obesity without MetS]. MetS was defined by modified International Diabetes Federation criteria. Biochemical analyses included fasting glucose, lipid profile, and liver enzymes on a Beckman Coulter AU5800 analyzer; insulin, cortisol, adrenocorticotropic hormone (ACTH), thyroid, and reproductive hormones on a Roche Cobas e601 electrochemiluminescence immunoassay system; and HbA1c by high-performance liquid chromatography (Bio-Rad D10). Serum phoenixin-14 was quantified by sandwich ELISA (Bioassay Technology Laboratory Cat. No. E7481Hu; sensitivity 8.19 ng/L; intra-assay CV 6.8%, interassay CV 9.2%). Group comparisons were performed using Mann–Whitney U and chi-square tests; a general linear model (GLM) adjusting for age and Tanner stage assessed the independent effect of the MetS and obese groups on serum phoenixin-14.

Results

Serum phoenixin-14 did not differ between the MetS and obese groups (519.75 ± 196.67 vs. 567.86 ± 368.40 pg/mL; p = 0.955). After adjustment for age and Tanner stage by GLM ( n = 95), the difference remained non-significant (adjusted difference: −26.5 pg/mL, 95% CI: −152.1 to 99.1; p = 0.676; adjusted means: MetS 529.1 pg/mL vs. Obese 555.7 pg/mL). Tanner stage was a significant covariate ( B = 73.04, p = 0.009). Children with MetS were older (13.62 ± 2.51 vs. 12.19 ± 2.65 years; p = 0.010) and had higher median insulin (30.80 vs. 18.20 µIU/mL; p < 0.001), higher triglycerides (172.04 ± 70.94 vs. 106.68 ± 39.27 mg/dL; p < 0.001), lower high-density lipoprotein-cholesterol (38.56 ± 7.73 vs. 47.02 ± 9.99 mg/dL; p < 0.001), and higher ACTH (28.86 ± 14.12 vs. 22.44 ± 11.86 pg/mL; p = 0.018).

Conclusions

In this cohort, serum phoenixin-14 did not differ between obese children with and without metabolic syndrome after adjusting for age and pubertal stage ( p = 0.676). These findings do not support a discriminative role for phoenixin-14 in pediatric MetS. Further studies including healthy normal-weight controls are needed to determine whether phoenixin-14 concentrations are altered in pediatric obesity.

Schlagwörter

Stichwörter der Autor:innen

adolescentinsulin resistancemetabolic syndromepediatric obesityphoenixin

Autor:innen und Institutionen

  • Department of Pediatrics, Konya City Hospital, University of Health Sciences, Konya, Türkiye.
  • Department of Pediatric Endocrinology, Konya City Hospital, Konya, Türkiye.
  • Department of Biochemistry, Konya City Hospital, Konya, Türkiye.
  • Department of Biochemistry, Fethiye State Hospital, Muğla, Türkiye.

Zitieren

APA

Bağcı, Z., Uyanık, R., Can, Ü., Yılmaz, D., & Akdu, S. (2026). Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1935719

Vancouver

Bağcı Z, Uyanık R, Can Ü, Yılmaz D, Akdu S. Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1935719

BibTeX
@article{Bac2026,
  author = {Bağcı, Zafer and Uyanık, Rukiye and Can, Ümmügülsüm and Yılmaz, Deniz and Akdu, Sadinaz},
  title = {Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1935719}
}
Kostenlos starten →